Several different types of colonoscopy prep regimens are available today, including prescription and over-the-counter options. While it is important to consult your healthcare provider for guidance, it can be helpful to conduct some of your own research.
The first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years is now available in the United States.
In a remarkable blend of adventure and advocacy, cousins John, Mitch, and Mike are gearing up for a cross-country charity journey along Route 66. Their mission? To raise awareness and support for two important causes: cystic fibrosis and colorectal cancer.
A veteran in the field of gastrointestinal cancer research, Dr. Marshall will share his leadership experience and scientific expertise to guide the Alliance’s patient support and research initiatives, particularly Project Cure CRC.
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
Explore the urgent need for the Colorectal Cancer Early Detection Act (HR 7714), legislation aimed at combating the rising incidence of colorectal cancer among younger adults through enhanced screening, education, and research.
People with RAS-mutated metastatic colorectal cancer (mCRC) have seen little progress in first-line treatment options over the past two decades, but that could soon change for thousands of new patients, according to a press release from Cardiff Oncology.
The BRAF gene is present in all the cells in our bodies. A BRAF mutation (a change or damage to the gene) is found in about 10% of colorectal cancer patients. If your biomarker tests show an abnormal BRAF mutation, treatments that target abnormal BRAF genes may be helpful. BRAF inhibitors are drugs that can turn off and stop mutated BRAF activity.
When colorectal cancer spreads, it can cause high or low levels of certain chemicals in the blood. Carcinoembryonic antigen, also called CEA, is a protein that may be elevated in colorectal cancer patients. High CEA levels can indicate your cancer has recurred or has spread beyond the colon. CEA is also sometimes higher in those who smoke or women who are pregnant. It may take additional testing to confirm the results of your CEA testing.
Our bodies have a gene that produces the dihydropyrimidine dehydrogenase enzyme, which helps break down certain medications in the liver. If there is mutation in the gene, your body will not produce enough of the dihydropyrimidine dehydrogenase enzyme. This condition is called dihydropyrimidine dehydrogenase deficiency (DPD).
Having DPD can cause fluorouracil-based chemotherapy drugs (which are commonly used in colon cancer treatment) to build up in your body and cause severely toxic reactions.
The HER2 protein is a receptor, which is a microscopic “spike” that sticks out on the surface of almost all the cells in our body. Sometimes there is an abnormality in the cell and multiple HER2 genes are produced, which is called amplification. When the HER2 gene is amplified, it produces excess receptors on the cell surface; this is called overexpression. Overexpression drives uncontrolled growth of the cells, which is how a cancer tumor forms.